Risankizumab Treatment Protocol for Chronic Plaque Psoriasis
Dosing and Administration
- The American Academy of Dermatology recommends a standard dosing regimen of 150 mg subcutaneously at weeks 0 and 4, then every 12 weeks thereafter, for the treatment of moderate-to-severe chronic plaque psoriasis 1
- Maintenance dosing of 150 mg every 12 weeks thereafter is recommended for patients with chronic plaque psoriasis 1
Efficacy Benchmarks
- The American Academy of Dermatology reports that 36-45% of patients achieve PASI 100 at week 16 when treated with risankizumab 2
Response Assessment Timeline
- Assess treatment response at 12 weeks of continuous therapy to determine definitive positive or negative response, as recommended by the American Academy of Dermatology 3
- For partial responders at 12 weeks, consider adding topical corticosteroids, vitamin D analogues, methotrexate, or ultraviolet B phototherapy, as suggested by the American Academy of Dermatology 3
Special Populations and Considerations
- Use caution in patients with pre-existing immunosuppression-related conditions, as recommended by the American Academy of Dermatology 2, 3
- Ensure prophylactic vaccination against pneumococcal and influenza infections before initiating therapy, as recommended by the American Academy of Dermatology 4
Safety Monitoring
- Screen for active infections, tuberculosis, and malignancy at baseline, as recommended by the American Academy of Dermatology 2
- Establish baseline respiratory status if respiratory comorbidities are present, as recommended by the American Academy of Dermatology 4
- Complete indicated vaccinations, as recommended by the American Academy of Dermatology 1
Treatment Interruption and Resumption
- Discontinue risankizumab approximately 3-4 half-lives before elective surgery, as recommended by the American Academy of Dermatology 1
- Resume risankizumab 1-2 weeks after surgery if no postoperative complications, as recommended by the American Academy of Dermatology 1
Comparative Positioning
- Risankizumab demonstrates superior efficacy compared to ustekinumab, with 75% vs 42% achieving PASI 90 at week 12, as reported by the American Academy of Dermatology 2
Risankizumab Therapy for Moderate to Severe Plaque Psoriasis
Safety Considerations
- The American Academy of Dermatology recommends using caution in patients with pre-existing immunosuppression-related conditions and active infections, which may require temporary discontinuation of risankizumab therapy 5
Pharmacokinetic Properties
- The bioavailability of risankizumab is 89% following subcutaneous administration, with a time to peak concentration of 3-14 days after dosing, and a terminal half-life of approximately 28 days, as reported by the Journal of the American Academy of Dermatology 5